5-isopropyl-1,1-dimethyl-biguanide | 102007-80-7

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 5-isopropyl-1,1-dimethyl-biguanide
• 英文别名: 5-Isopropyl-1,1-dimethyl-biguanid；1,1-dimethyl-2-(N'-propan-2-ylcarbamimidoyl)guanidine
• CAS: 102007-80-7
• 化学式: C₇H₁₇N₅
• 分子量: 171.245
• InChiKey: VIOSIKUANQXQAZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.5
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  80
• 氢给体数：
  2
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  异丙基氨盐酸盐 、 alkaline earth salt of/the/ methylsulfuric acid 生成 5-isopropyl-1,1-dimethyl-biguanide
  参考文献：
  名称：

  Hypoglycemic Agents. IV.^1—3 N¹,N⁵-Alkyl- and Aralkylbiguanides

  摘要：

  DOI：

  10.1021/ja01526a047

文献信息

• FATTY ACID GUANIDINE AND SALICYLATE GUANIDINE DERIVATIVES AND THEIR USES
  申请人：Milne Jill C.

  公开号：US20120277305A1

  公开（公告）日：2012-11-01

  The invention relates to fatty acid guanidine or salicylate guanidine derivatives; compositions comprising an effective amount of a fatty acid guanidine or salicylate guanidine derivative; and methods for treating or preventing a metabolic disease comprising the administration of an effective amount of a fatty acid guanidine or salicylate guanidine derivative.

  这项发明涉及脂肪酸胍或水杨酸胍衍生物；包含有效量脂肪酸胍或水杨酸胍衍生物的组合物；以及治疗或预防代谢性疾病的方法，包括给予有效量脂肪酸胍或水杨酸胍衍生物。
• USE OF PRODRUGS TO AVOID GI MEDIATED ADVERSE EVENTS
  申请人：Franklin Richard

  公开号：US20120202756A1

  公开（公告）日：2012-08-09

  The present invention relates to prodrugs of a wide variety of drugs and pharmaceutical compositions containing such prodrugs. Methods for minimizing locally mediated (from within the gut lumen) adverse gastrointestinal events associated with the underivatised drug and increasing the sustainment of plasma drug levels with the aforementioned prodrugs are also provided. Thus, the present invention relates to the use of prodrugs of a wide diversity of drugs (other than opioids) to transiently inactivate them and so reduce directly, locally mediated adverse gastrointestinal (GI) side-effects normally evident after administration of the parent compound. Additionally, such prodrugs may confer improved pharmacokinetics.

  本发明涉及各种药物的前药和含有这些前药的制药组合物。还提供了一种方法，用于最小化与未衍生药物相关的局部介导（来自肠腔内）不良胃肠事件，并使用上述前药增加血浆药物水平的持续性。因此，本发明涉及使用各种药物（除阿片类药物外）的前药，以短暂地使它们失活，从而减少通常在给予原始化合物后出现的直接、局部介导的不良胃肠（GI）副作用。此外，这些前药可能提供改善的药代动力学。
• Dihydro-1,3,5-triazine amine derivatives and their therapeutic uses
  申请人：Moinet Gerard

  公开号：US20080108619A1

  公开（公告）日：2008-05-08

  The invention relates to the compounds of general formula (I): in which R1, R2, R3, R4, R5 and R6 are as defined in Claim 1. These compounds can be used in the treatment of pathological conditions associated with the insulin-resistance syndrome.
• US7452883B2
  申请人：——

  公开号：US7452883B2

  公开（公告）日：2008-11-18
• US7767676B2
  申请人：——

  公开号：US7767676B2

  公开（公告）日：2010-08-03